A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

Recruiting now · Phase 2

Conditions studied: Solid Tumors

In brief

This is an open-label, multicenter Phase 2 study evaluating BMS-986504 in participants with advanced and/or metastatic solid tumors that have MTAP deletion. The study includes a monotherapy component and a combination component in which BMS-986504 is given with other anti-cancer agents. The trial will assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of BMS-986504 alone and in combination regimens.

Key facts

Study ID

NCT07492680

Run by

Bristol-Myers Squibb

People needed

260

Starts

2026-07-27

Expected to finish

2032-05-20

Last updated by the study team

2026-07-30

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participant must have histologically confirmed diagnosis of advanced and/or metastatic solid tumor malignancy with homozygous deletion of the MTAP gene detected in tumor tissue.
• Depending on the cohort enrolled, participants must have received standard therapies appropriate for their tumor type and stage with disease progression on or after the most recent treatment (there must be no available treatment with curative intent or participant is ineligible or declines treatment) or be treatment-naïve with no prior systemic anticancer therapy for their unresectable or metastatic disease.
• Participant must have presence of at least one measurable tumor lesion per RECIST v1.1 or mRECIST at baseline.
• Coagulation function: International normalized ratio (INR) and activated partial thromboplastin time (APTT) must be ≤ 1.5 × ULN; subjects with liver metastasis or liver cancer must be ≤ 2 × ULN.
• Participant must have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

You may not qualify if…

• Participants must not have prior treatment with a PRMT5 or Methionine adenosyl transferase 2A (MAT2A) inhibitor.
• Participants must not have active brain metastases or carcinomatous meningitis. Participants are eligible if brain metastases are adequately treated, and participants are neurologically stable for at least 2 weeks prior to enrollment without the use of corticosteroids or are on a stable or decreasing dose of ≤ 10 mg daily prednisone (or equivalent).
• Participants must not have history of gastrointestinal disease or other gastrointestinal conditions within 6 months prior to enrollment (including uncontrolled nausea, vomiting, malabsorption syndrome or non-gastrointestinal fistula, gastrointestinal perforation, or intra-abdominal abscess) likely to alter absorption of study treatment or result in inability to swallow oral medications.
• Participants must not have inadequate organ function, as determined by laboratory testing within the screening period.
• Participants must not have active viral HBV or HCV hepatitis.
• Other protocol defined inclusion/exclusion criteria applies.

Where it is running

• National Cancer Center Hospital — Chuo-ku, Tokyo, Japan (enrolling)
• Fudan University Shanghai Cancer Center — Shanghai, Shanghai Municipality, China (enrolling)
• Shanghai GoBroad Cancer Hospital China Pharmaceutical University — Shanghai, Shanghai Municipality, China (enrolling)
• Johns Hopkins Hospital — Baltimore, Maryland, United States (enrolling)
• Local Institution - 0119 — Ann Arbor, Michigan, United States
• Local Institution - 0129 — Rochester, Minnesota, United States
• Local Institution - 0178 — Atlanta, Georgia, United States
• Local Institution - 0142 — Buffalo, New York, United States
• Local Institution - 0124 — Boston, Massachusetts, United States
• Local Institution - 0170 — New York, New York, United States
• Local Institution - 0139 — New York, New York, United States
• Local Institution - 0100 — Durham, North Carolina, United States
• Local Institution - 0085 — Houston, Texas, United States
• Local Institution - 0086 — Seattle, Washington, United States
• Local Institution - 0114 — Ghent, Oost-Vlaanderen, Belgium
• Local Institution - 0181 — Rochester, Minnesota, United States
• Local Institution - 0148 — Brussels, Bruxelles-Capitale, Région de, Belgium
• Local Institution - 0051 — Vancouver, British Columbia, Canada
• Local Institution - 0021 — Toronto, Ontario, Canada
• Local Institution - 0007 — Toronto, Ontario, Canada
• Local Institution - 0155 — Beijing, Beijing Municipality, China
• Local Institution - 0185 — Chongqing, Chongqing Municipality, China
• Local Institution - 0184 — Guangzhou, Guangdong, China
• Local Institution - 0152 — Xinxiang, Henan, China
• Local Institution - 0134 — Madison, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.